On November 7, Elon Musk posted on X, seemingly congratulating Donald Trump on his victory in the 2024 U.S. presidential election.

Elon Musk celebrated Donald Trump's victory with bold symbolism, declaring "Novus Ordo Seclorum"—a new order. Throughout the campaign, Musk rallied support on social media, and as results rolled ...

Coeptis Therapeutics (NASDAQ:COEP) just reported results for the second quarter of 2024. Coeptis Therapeutics reported earnings per share of -8 cents. The company did not report any revenue for ...

We recently published a list of Top 10 Must-See AI News And Ratings For Investors. In this article, we are going to take a look at where Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) stands ...

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious ...

14:53 EST Coeptis Therapeutics (COEP) Holdings Inc trading halted, volatility trading pause Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and ...

WEXFORD, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is ...

Read about Coeptis Therapeutics Holdings Inc Ordinary Shares (COEP:XNAS) stock and today's latest news and financial updates.

Coeptis Therapeutics (COEP) announced the expansion of its license agreement with Deverra Therapeutics, broadening the potential applications of its allogeneic natural killer cell technology.

Coeptis' President and CEO, Dave Mehalick, expressed satisfaction with Nasdaq's decision and reiterated the company's commitment to complying with listing requirements.

Coeptis Therapeutics Holdings Inc. (COEP) latest news, insider trading and hedge fund ownership data provided by Insider Monkey.